Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.
Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...
Zacks.com on MSN10d
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...
Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback